His scientific interests lie mostly in Internal medicine, Colorectal cancer, Surgery, Fluorouracil and Chemotherapy. His Internal medicine research includes elements of Gastroenterology and Oncology. The Colorectal cancer study combines topics in areas such as Rectum, Randomized controlled trial and Adjuvant therapy.
His Surgery research incorporates elements of Adjuvant, Primary tumor and Disease. His Fluorouracil research is multidisciplinary, incorporating perspectives in Regimen, Irinotecan, Carcinoma, Nausea and Radiation therapy. His Chemotherapy study combines topics from a wide range of disciplines, such as Survival rate, Levamisole, Metastasis and Incidence.
His primary scientific interests are in Internal medicine, Colorectal cancer, Oncology, Surgery and Chemotherapy. Internal medicine is closely attributed to Gastroenterology in his research. Michael J. O'Connell has included themes like Adjuvant, Fluorouracil, Rectum and Adjuvant therapy in his Colorectal cancer study.
His research in Oncology focuses on subjects like Hazard ratio, which are connected to Proportional hazards model. His work in Surgery tackles topics such as Disease which are related to areas like Radiology. The various areas that he examines in his Chemotherapy study include Survival rate, Incidence and Lymphoma.
His main research concerns Colorectal cancer, Internal medicine, Oncology, Oxaliplatin and Surgery. His Colorectal cancer research incorporates themes from Gastroenterology, Adjuvant, Clinical trial and Chemotherapy. Michael J. O'Connell has researched Oncology in several fields, including Body mass index, Randomized controlled trial, Lymph node, Pathology and Irinotecan.
The concepts of his Oxaliplatin study are interwoven with issues in Bevacizumab, Regimen, Clinical endpoint and Capecitabine. His work in the fields of Survival analysis overlaps with other areas such as Cryoablation. The study incorporates disciplines such as Radiation therapy and Bolus in addition to Fluorouracil.
Colorectal cancer, Internal medicine, Oxaliplatin, Fluorouracil and Oncology are his primary areas of study. Michael J. O'Connell combines subjects such as Clinical trial, Surgery, Chemotherapy, Adjuvant therapy and Hazard ratio with his study of Colorectal cancer. Michael J. O'Connell has researched Chemotherapy in several fields, including Asymptomatic and Primary tumor.
His Oxaliplatin research integrates issues from Bevacizumab, Regimen, Chemotherapy regimen and Capecitabine. The Fluorouracil study combines topics in areas such as Gastroenterology and Radiation therapy. Michael J. O'Connell works mostly in the field of Oncology, limiting it down to topics relating to Cancer and, in certain cases, Body mass index, Overweight and Prospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group
C. G. Moertel;S. Frytak;R. G. Hahn;M. J. O'Connell.
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery
Michael J. O'Connell;James A. Martenson;Harry S. Wieand;James E. Krook.
The New England Journal of Medicine (1994)
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Larry K. Kvols;Charles G. Moertel;Michael J. O'Connell;Allan J. Schutt.
The New England Journal of Medicine (1986)
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms
Charles G. Moertel;Larry K. Kvols;Michael J. O'Connell;Joseph Rubin.
Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03
Mark S. Roh;Linda H. Colangelo;Michael J. O'Connell;Greg Yothers.
Journal of Clinical Oncology (2009)
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1.
Stephen N. Thibodeau;Amy J. French;Julie M. Cunningham;David Tester.
Cancer Research (1998)
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison.
Charles G. Moertel;Thomas R. Fleming;Edward T. Creagan;Joseph Rubin.
The New England Journal of Medicine (1985)
Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials
Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray.
Journal of Clinical Oncology (2004)
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra;Greg Yothers;Michael J. O'Connell;Saima Sharif.
Journal of Clinical Oncology (2011)
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial.
Edward T. Creagan;Charles G. Moertel;Judith R. O'Fallon;Allan J. Schutt.
The New England Journal of Medicine (1979)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: